Skip to main content
SpringerLink
Log in

Oral Contraceptives and the Risk of Ductal Breast Carcinoma in situ

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Recent evidence suggests that oral contraceptive use is associated with little to no increased risk of invasive breast carcinoma. No study has examined the relationship between oral contraceptive use and the risk of non-invasive breast carcinoma, that is, breast carcinoma in situ.

Objective. To define the role of oral contraceptive use in the development of breast carcinoma in situ.

Methods. The data are 875 ductal carcinoma in situ (DCIS) cases diagnosed among residents of the state of Connecticut from September 15, 1994 to March 14, 1998 and between the age of 20 and 79 years as well as 999 control subjects. Controls are female Connecticut residents collected via random-digit-dial and frequency matched to the cases by 5-year age intervals. Telephone interviews were used to collect information on risk factors and cancer screening history. Logistic regression was used to provide maximum likelihood estimates of the odds ratios (OR) with 95% confidence intervals (95% CI).

Results. The risk of being diagnosed with DCIS for women who had ever used oral contraceptives was not increased relative to women who had never used them (OR: 1.0, 95% CI: 0.8, 1.2). The risk did not significantly increase with duration of oral contraceptive use, nor with duration of high estrogen use, time since last use, progestin or estrogen type, or age at first use. Furthermore, the association between oral contraceptive use and DCIS risk did not vary by the presence of a family history of breast cancer or by menopausal status.

Conclusions. In these data, no evidence was found for an increased risk of ductal carcinoma in situ associated with the use of oral contraceptives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of breast cancer. N Engl J Med 315: 405–411, 1986

    Google Scholar 

  2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies: Lancet 347: 1713–1727, 1996

    Google Scholar 

  3. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al.: Oral contraceptives and the risk of breast cancer. N Engl J Med 346: 2025–2032, 2002

    Google Scholar 

  4. Davidson NE, Helzlsouer KJ: Editorial. Good news about oral contraceptives. N Engl J Med 346: 2078–2079, 2002

    Google Scholar 

  5. Millikan R, Dressler L, Geradts J, Graham M: The need for epidemiologic studies of in situ carcinoma of the breast. Breast Cancer Res Treat 35: 65–77, 1995

    Google Scholar 

  6. Weiss HA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, Schoenberg JB, Swanson CA: Epidemiology of in situ and invasive breast cancer in women aged under 45. Brit J Cancer 73: 1298–1305, 1996

    Google Scholar 

  7. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK: Risk factors for in situ breast cancer. Cancer Epidemiol, Biomarkers Prev 5: 961–965, 1996

    Google Scholar 

  8. Brinton LA, Hoover R, Fraumini Jr JF: Epidemiology of minimal breast cancer. JAMA 249: 483–487, 1983

    Google Scholar 

  9. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V: Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. JNCI 89: 77–82, 1997

    Google Scholar 

  10. Newcomb P, Storer BE, Marcus PM: Risk factors for carcinoma in situ of the breast. Abstract, American Society of Preventive Oncology, Bethesda, MD, 1994

    Google Scholar 

  11. Claus EB, Risch NR, Thompson WD, Carter D: Relationship between breast histopathology and family history of breast cancer. Cancer 71: 147–153, 1993

    Google Scholar 

  12. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO: Parity, age at first birth and the risk of carcinoma in situ of the breast. Intl J Cancer 77: 330–332, 1998

    Google Scholar 

  13. Saltzstein SL: An epidemiologic study of differences between mammary ductal and lobular carcinoma in situ: analysis of 11,436 case patients from the California Cancer Registry. Anat Pathol 1: 193–203, 1996

    Google Scholar 

  14. Dubin N, Hutter RVP, Strax P, Fazzini E, Schinella RA, Batang E, et al.: Epidemiology of minimal breast cancer among women screened in New York City. J Natl Cancer Inst 73: 1273–1279, 1984

    Google Scholar 

  15. Press MF, Bernstein L: Molecular epidemiology of breast carcinoma in situ. The US Army Medical Research and Material Command Annual Meeting, Atlanta 2000

  16. Claus EB, Stowe M, Carter D: Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93: 1811–1817, 2001

    Google Scholar 

  17. Colditz GA, Manson JE, Hankinson SE: The Nurses health study: 20-year contribution to the understanding of health among women. J Womens Health 6: 49–62, 1997

    Google Scholar 

  18. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC: Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94: 32–38, 2002

    Google Scholar 

  19. Covington TR, Dipalma JR, Hussar DA, Lasagna L, Tatro DS, Whitsett TL (eds) Hormones. In: Drug Facts and Comparisons. J.B. Lippincott Co., St. Louis, MO, 1986

  20. SAS: SAS/STAT User's Guide, Version 6, 4th edn, vol 1. SAS Institute Inc., Cary, NC, 1989

    Google Scholar 

  21. ACS Guidelines for the early detection of breast cancer: Update 1997. CA Cancer J Clin 47(3): 150–153, 1997

    Google Scholar 

  22. NIH Consensus Statement Online 1997 Jan 21-23; 15(1): 1-35. http://odp.od.nih.gov/consensus/cons/103/103_ statement.htm

  23. Breast Cancer Screening for Women Ages 40-49: NIH Consensus Statement Online 1997 Jan 21-23; 15(1): 1-35. http://odp.od.nih.gov/consensus/cons/103/103_statement.htm

  24. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, Bernstein L: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57: 3678–3681, 1997

    Google Scholar 

  25. Grabick DW, Hartman LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284: 1791–1798, 2000

    Google Scholar 

  26. Ursin G, Li C, Pike M: Should women with a family history of breast cancer avoid use of oral contraceptives? Epidemiol 11: 615, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

    Elizabeth B. Claus & Meredith Stowe

  2. Department of Pathology, Yale University School of Medicine, New Haven, CT, USA

    Darryl Carter

Authors
  1. Elizabeth B. Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meredith Stowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darryl Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Claus, E.B., Stowe, M. & Carter, D. Oral Contraceptives and the Risk of Ductal Breast Carcinoma in situ . Breast Cancer Res Treat 81, 129–136 (2003). https://doi.org/10.1023/A:1025728524310

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025728524310

Search

Navigation